chicago-biotech
(2)
Nobu Ueki Is Looking for Cancer's Off Switch
The Chicago scientist built a career around a stubborn question: can a drug wait until a cancer cell gives it permission to act? His answer spans two molecular locks, one active US patent, and a startup betting on the peculiar weakness of cells in transit.
Caralynn Nowinski Collens
Caralynn Nowinski Collens is a physician-turned-entrepreneur and the co-founder and CEO of Dimension Bio (formerly Dimension Inx), a Chicago biotechnology company building regenerative therapeutics that give the body a blueprint to heal itself. Its BioNidum platform fuses materials science, 3D-printing, and digital manufacturing to turn cells into implantable, tissue-like therapies. Before biotech, she spent eight years co-founding and running UI LABS, the innovation collaborative that launched MxD, the U.S. national hub for digital manufacturing. She trained as an M.D./MBA at the University of Illinois at Chicago and has been recognized on Crain's Forty Under Forty, Tech 50, and Notable Women in STEM lists.